Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Kenai Therapeutics a biotechnology company leveraging induced pluripotent stem cell iPSC technology to discover and develop a platform of allogeneic neuron replacement cell therapies for neurological disorders today announced an 82 million Series A financing coled by Alaska Permanent Fund Corporation Cure Ventures and The Column Group with participation from Euclidean Capital and Saisei Ventures.
Parkinson's disease, the second most common type of progressive dementia after Alzheimer's disease, affects nearly 1 million people in the U.S. and an estimated 10 million individuals worldwide.
<p>In a new study, <a href="https://search.asu.edu/profile/3942692">Jeffrey Kordower</a>, director of the <a href="https://biodesign.asu.edu/neurodegenerative-disease/">ASU-Banner Neurodegenerative Disease Research Center</a>, and his colleagues unveil pivotal insights into the progression of Parkinson's disease, presenting new hope for patients battling the severely debilitating disorder.</p>
<p>The research highlights the role of a critical protein called tau in the early stages of the disease. The results suggest that aggregates of the tau protein may jump-start processes of neuronal damage and death characteristics of the disease.</p>